Pharmaceutical

EC approves MSD’s pneumococcal 21-valent conjugate Capvaxive

MSD has received approval from the EC for Capvaxive, a pneumococcal 21-valent conjugate vaccine, to prevent invasive disease and pneumonia.

Mar 27, 2025 - 06:00
EC approves MSD’s pneumococcal 21-valent conjugate Capvaxive
MSD has received approval from the EC for Capvaxive, a pneumococcal 21-valent conjugate vaccine, to prevent invasive disease and pneumonia.
Read the original article

Tags:

Previous Article

Research Highlights Importance of Genetics and Genomic Medicine Knowledge for Pe...

Next Article

EU Health Data Space strikes a chord in EU harmonisation plans

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Investigators fault Lilly plant for manufacturing issues

Investigators fault Lilly plant for manufacturing issues

Jan 22, 2024

Signal: NHS whistle-blower policy questioned following Letby conviction

Signal: NHS whistle-blower policy questioned following ...

Aug 26, 2023

FDA approves Duchenne gene therapy with hefty $3.2m price tag

FDA approves Duchenne gene therapy with hefty $3.2m pri...

Jun 23, 2023